Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies for COVID-19 Vaccine Adjuvant
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced entering into a material transfer agreement with Adjuvance Technologies Inc. for use of the adjuvant TQL1055 in the Company’s Terra CoV-2 vaccine against COVID-19.
Oragenics CEO Alan Joslyn Recognized As Health Care Innovator 2020 on Tampa Bay Business Journal
The Tampa Bay Business Journal recognized Alan Joslyn, president and chief executive officer of UF startup and UF Innovate | Sid Martin Biotech graduate... Read More
FDA Broadly Supports Oragenics’ Pre-IND Development Program for Its SARS-CoV-2 Vaccine
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and... Read More
Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., and Avid Bioservices, Inc., announced that they have entered into a process... Read More
Tiny Florida Medical Research Firm Faces Giant Challenge — COVID-19 Vaccine
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a Tampa-based medical research business with roots in Gainesville, found itself at... Read More
Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and... Read More
How to Create a COVID-19 Vaccine
Alan Joslyn Ph.D. president and CEO of UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the... Read More
Oragenics Inc. and Aragen Bioscience Enter Agreement to Accelerate Development of TerraCoV2, a COVID 19 Vaccine Candidate
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and... Read More
After Acquisition, Tampa Biotech Firm Looks Toward COVID-19 Vaccine
Serendipity is the word Alan Joslyn uses to describe the meeting and eventual acquisition of a Gainesville-based biotech firm. “It’s not every... Read More
Oragenics Acquires Noachis Terra Inc., to Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing “Spike Protein”
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against... Read More